CeriBell, Inc.
CBLLCeriBell is a medical technology company that develops and commercializes an AI-powered point-of-care EEG platform for the acute care setting.
Earnings
Next report
Aug 4, 2026 (in a month)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
Profile
CeriBell is a medical technology company that develops and commercializes an AI-powered point-of-care EEG platform for the acute care setting. The company's system combines portable hardware with proprietary algorithms to enable rapid diagnosis and continuous monitoring of neurological conditions like seizures and delirium. Its core value proposition is reducing the time to EEG diagnosis from hours to minutes, thereby improving patient outcomes and hospital economics.
CeriBell holds a first-mover advantage as the provider of the first FDA-cleared device for diagnosing electrographic status epilepticus and delirium using AI-powered point-of-care EEG.
Questions, answered.
- What is CeriBell, Inc.'s market cap?
- CeriBell, Inc. (CBLL) has a market capitalization of $748.6M and trades on XNAS.
- What is CeriBell, Inc.'s revenue and profitability?
- CeriBell, Inc. generated $95.1M in trailing twelve-month revenue with a net loss of $60.4M, representing a net margin of -63.5%. Gross margin stands at 87.7%, with free cash flow of -$49.4M. These figures are based on the Q1 2026 filing.
- Who are CeriBell, Inc.'s competitors?
- CeriBell, Inc.'s key competitors include Integra LifeSciences Holdings, iRhythm Holdings, Inc. Common Stock, ClearPoint Neuro, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does CeriBell, Inc. partner with?
- CeriBell, Inc.'s notable partners include Stanford University, Shenzhen Everwin Precision Technology Co., Ltd., Centers for Medicare and Medicaid Services.
- Where is CeriBell, Inc. headquartered?
- CeriBell, Inc. is headquartered in United States of America. It has been publicly traded since 2024.
